Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 17/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.66 |
| ▸ | PTGIS | Q16647 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13252910 | 1.00 | TBXAS1 (0.74) | TBXAS1TBXA2RPTGISMEN1CYP1A2 | |
| SCHEMBL10354335 | 1.00 | TBXAS1 (0.74) | TBXAS1TBXA2RPTGISMEN1CYP1A2 | |
| SCHEMBL9650298 | 0.93 | TBXA2R (0.69) | TBXAS1TBXA2RPTGISMEN1CYP1A2 | |
| SCHEMBL13252905 | 0.90 | TBXAS1 (0.62) | TBXAS1TBXA2RPTGISMEN1CYP1A2 | |
| SCHEMBL10471085 | 0.89 | TBXAS1 (0.94) | TBXAS1TBXA2RPTGIS | |
| SCHEMBL13252899 | 0.89 | TBXA2R (0.82) | TBXAS1TBXA2RPTGISMEN1CYP1A2 | |
| SCHEMBL10075099 | 0.87 | TBXAS1 (0.57) | TBXAS1TBXA2RPTGISMEN1CYP1A2 | |
| SCHEMBL9161927 | 0.85 | TBXAS1 (1.00) | TBXAS1TBXA2RPTGIS | |
| SCHEMBL10354163 | 0.84 | TBXAS1 (0.73) | TBXAS1TBXA2RPTGIS | |
| SCHEMBL10466750 | 0.83 | CYP1A2 (0.68) | TBXAS1TBXA2RPTGISCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | PPARD, PPARG, PPARA | TBXAS1 81/4885TBXA2R 48/4885PTGIS 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.